NovoCure Limited · NASDAQ:NVCR
NovoCure — Q2 2023 Earnings Presentation
13 slides from NovoCure's earnings presentation, Jul 27, 2023
Slide 1: Novocure Q2 2023 Earnings
novecure’ Novocure Q2 2025 Earnings Thursday, July 27, 2023 patientforward
Slide 2: Forward-looking statements
novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding a
Slide 3: A comprehensive strategy for long-term growth
novecure’ a comprehensive strategy for long-term growth advance drive commercial deliver clinical trials adoption product innovation to reach new patient in approved to increase dose and populations indications duration of therapy Built upon a foundation of financial strength and a robust intellectu
Slide 4: Phase 3 LUNAR trial met primary overall survival endpoint
novecure’ phase 5 LUNAR trial met primary overall survival endpoint Overall survival (ITT population) Overall survival (ICl-treated patients) 10 1.0 09 09 Median OS (months) 13.2 9.9 Median OS (months) 18.5 10.8 08 Log-rank P-value 0.035 08 Log-rank P-value 0.03 <= 07 HR (95% Ci) 0.74 (0.56-0.98) 07
Slide 5: Planned commercial pathway to treat NSCLC patients
novecure’ planned commercial pathway to treat NSCLC patients 0 2023 5 2024 2025 L COMMERCIAL LAUNCH * Activate physici d REGULATORY PATHWAY ee Een an patient education CLINICAL DATA v Initiate pre-PMA discussions programs y, ; with FDA * Treat on-protocol patients ABOUTISSS (eyllnts HESS Y Submit CE
Slide 6: LUNAR-2 phase 3 trial in non-small cell lung cancer
novecure’ LUNAR-2 phase 3 trial in non-small cell lung cancer RANDOMIZED, OPEN-LABEL TRIAL TREATING METASTATIC NON-SMALL CELL LUNG CANCER CT/follow-up q3w until progression TTFields + pembrolizumab + platinum-based chemotherapy survival follow-up screening and baseline evaluation CT/follow-up q3w un
Slide 7: Multiple phase 3 trials set to readout by year-end 2024
novecure’ multiple phase S trials set to readout by year-end 2024 with potential to treat many more patients (@) LUNAR o) METIS Lung Cancer Brain Metastasis ENGOT-ov50/ INNOVATE-3 ; Ovarian Cancer patientforward © 2023Novocure GmbH 7 PANOVA-3 Pancreatic Cancer
Slide 8: Q2 2023 selected financial highlights
q2 2025 selected financial highlights U.S. DOLLARS IN THOUSANDS Q2 2023 Q2 2022 % CHANGE Net revenues 126,051 $ 140,866 -11% Cost of revenues 34,018 28,503 19% Gross profit 92,033 112,363 -18% Research, development and clinical trials 55,427 57,075 -3% Sales and marketing 58,488 44,750 31% General a
Slide 9: Together with our patients, we strive to extend survival
novocure’ » together with our patients, we Strive to extend survival in some of the most aggressive forms of cancer patientforward
Slide 10: Optune Lua and Optune indications for use and important safety information
novecure’ Optune Lua® and Optune® indications for use and important safety information INDICATIONS Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of a
Slide 11: Optune Lua and Optune indications for use and important safety information
novecure’ Optune Lua® and Optune® indications for use and important safety information WARNINGS AND PRECAUTIONS » Optune and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. * The most common (210%) adverse event
Slide 12: Appendix
Slide 13: Adjusted EBITDA reconciliation
novocure adjusted EBITDA reconciliation Adjusted EBITDA is a non-GAAP measurement of earnings before interest, taxes, depreciation, amortization and share-based compensation. We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare